
$ABCL vs.$RXRX: The $800M Hot Flash vs. The Phenomics Paradox
·7 min read
In the era where biology meets computation, two very different approaches to industrialising drug discovery: AbCellera ($ABCL) and Recursion Pharmaceuticals ($RXRX). Both were born from the ambition
In the era where biology meets computation, two very different approaches to industrialising drug discovery: AbCellera ($ABCL) and Recursion Pharmaceuticals ($RXRX). Both were born from the ambition to industrialize drug discovery, yet their architectures couldn't be more different. One is the precision engineer of complex antibodies; the other, the digital architect mapping biology's cellular landscape. With both companies having delivered their Q3 2026 earnings updates in November 2026, recent
8
0
0
0
